Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick exercised stock options for 20,000 shares of common stock at an exercise price of
The filing states these transactions were completed under a pre-arranged Rule 10b5-1 trading plan dated
Jeremy Chadwick reported proposed and recent transactions in shares of KYMR. The filing lists a proposed exercise-related sale of 20,000 common shares dated 03/11/2026 and shows restricted stock units dated 05/22/2024 totaling 5,758 units.
The filing also records completed sales: 3,919 shares on 03/04/2026 for $334,272.49 and 2,039 shares on 03/02/2026 for $181,321.64.
Kymera Therapeutics reported that Chief Legal Officer Brian Adams received new equity awards. He was granted a stock option for 8,250 shares at an exercise price of $0.00 per share, and 4,125 shares of common stock in the form of restricted stock units. The RSUs vest in four equal annual installments following March 2, 2026, while the stock option vests in 48 equal monthly installments following the same date, in each case contingent on continued employment.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of equity awards and share sales. On March 2, 2026 he received 12,575 restricted stock units that vest in three equal annual installments following March 3, 2025, plus a stock option for 25,150 shares vesting in 48 equal monthly installments following March 2, 2026. That same day he sold 2,039 common shares in open‑market transactions, including shares sold automatically to cover tax withholding on vesting RSUs. On March 4, 2026 he sold an additional 3,919 common shares in open‑market transactions at weighted average prices ranging from $83.9965 to $89.6574 per share. After these transactions he directly owned 73,810 Kymera common shares, in addition to the newly granted option award.
Kymera Therapeutics, Inc. reported that Chief Business Officer Noah Goodman received new equity awards. On March 2, 2026, he was granted a stock option for 18,450 shares at an exercise price of $0.00 per share and 9,225 shares of common stock in the form of restricted stock units. Following the RSU grant, his direct common stock holdings increased to 59,306.438 shares. The RSUs vest in four equal annual installments after March 2, 2026, while the option vests in 48 equal monthly installments after that date, in each case conditioned on continued employment.
Kymera Therapeutics Chief Medical Officer Jared Gollob reported multiple insider transactions. He sold a net 10,508 shares of common stock in several open-market sales on March 2 and March 4, 2026, at weighted average prices in the mid-$80s per share. On March 2, he also received 17,650 restricted stock units that vest in four equal annual installments after March 2, 2026, and a stock option for 35,300 shares vesting in 48 equal monthly installments, all subject to continued employment. Certain March 2 sales were automatically executed to cover tax withholding from RSU vesting and were not at his discretion.
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of share sales and new equity awards. Across several open-market transactions on
On
Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported receiving a grant of stock options for 215,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
According to the disclosure, the options vest in forty-eight equal monthly installments following March 2, 2026, and each portion will vest only if Mainolfi remains employed through the applicable vesting date. All 215,000 stock options are held as direct ownership following this transaction.
Kymera Therapeutics, Inc. director-associated venture funds reported open-market sales of a combined 81,866 shares of common stock at a weighted average price of about $90.13 per share. Atlas Venture Fund X, L.P. sold 71,814 shares and Atlas Venture Opportunity Fund I, L.P. sold 10,052 shares on March 2, 2026.
These trades were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025. Bruce Booth is a member of the general partner entities of these funds and disclaims Section 16 beneficial ownership of the funds’ holdings except to the extent of his pecuniary interest.